ERAS vs. ASND
ERAS (Erasca, Inc.) and ASND (Ascendis Pharma A/S) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 3 years, ERAS returned 68.63%/yr vs 32.88%/yr for ASND. At a 0.30 correlation, their price movements are largely independent.
Performance
ERAS vs. ASND - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ERAS achieves a 277.69% return, which is significantly higher than ASND's 2.26% return.
ERAS
- 1D
- 0.29%
- 1M
- 37.34%
- YTD
- 277.69%
- 6M
- 290.28%
- 1Y
- 849.32%
- 3Y*
- 68.63%
- 5Y*
- —
- 10Y*
- —
ASND
- 1D
- 1.14%
- 1M
- -9.33%
- YTD
- 2.26%
- 6M
- -1.07%
- 1Y
- 27.67%
- 3Y*
- 32.88%
- 5Y*
- 10.86%
- 10Y*
- 33.14%
ERAS vs. ASND - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
ERAS Erasca, Inc. | 277.69% | 48.21% | 17.84% | -50.58% | -72.34% | -2.01% |
ASND Ascendis Pharma A/S | 2.26% | 54.89% | 9.31% | 3.13% | -9.22% | 9.58% |
Correlation
The correlation between ERAS and ASND is 0.21, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.21 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.25 |
Correlation (All Time) Calculated using the full available price history since Jul 16, 2021 | 0.30 |
Fundamentals
ERAS:
$4.28B
ASND:
$14.07B
ERAS:
-$0.96
ASND:
€8.08
ERAS:
10.86
ASND:
24.89
ERAS:
$0.00
ASND:
€867.51M
ERAS:
-$743.00K
ASND:
€764.89M
ERAS:
-$279.47M
ASND:
-€6.94M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ERAS vs. ASND — Risk / Return Rank
ERAS
ASND
ERAS vs. ASND - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Erasca, Inc. (ERAS) and Ascendis Pharma A/S (ASND). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ERAS | ASND | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +7.19 | ||
| Sortino ratioReturn per unit of downside risk | +3.13 | ||
| Omega ratioGain probability vs. loss probability | 1.71 | 1.15 | +0.55 |
| Calmar ratioReturn relative to maximum drawdown | 13.90 | 1.59 | +12.31 |
| Martin ratioReturn relative to average drawdown | 43.69 | 4.87 | +38.82 |
Loading charts...
Drawdowns
ERAS vs. ASND - Drawdown Comparison
The maximum ERAS drawdown since its inception was -95.65%, which is greater than ASND's maximum drawdown of -61.72%. Use the drawdown chart below to compare losses from any high point for ERAS and ASND.
Loading charts...
Drawdown Indicators
| ERAS | ASND | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.65% | -61.72% | -33.93% |
Max Drawdown (1Y)Largest decline over 1 year | -59.46% | -17.62% | -41.84% |
Max Drawdown (3Y)Largest decline over 3 years | -67.68% | -29.15% | -38.53% |
Max Drawdown (5Y)Largest decline over 5 years | — | -60.46% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -61.72% | — |
Current DrawdownCurrent decline from peak | -42.28% | -12.72% | -29.56% |
Average DrawdownAverage peak-to-trough decline | -74.66% | -18.90% | -55.76% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 18.96% | 5.72% | +13.24% |
Volatility
ERAS vs. ASND - Volatility Comparison
Erasca, Inc. (ERAS) has a higher volatility of 20.78% compared to Ascendis Pharma A/S (ASND) at 13.12%. This indicates that ERAS's price experiences larger fluctuations and is considered to be riskier than ASND based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ERAS | ASND | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 20.78% | 13.12% | +7.66% |
Volatility (6M)Calculated over the trailing 6-month period | 96.05% | 29.45% | +66.60% |
Volatility (1Y)Calculated over the trailing 1-year period | 104.00% | 37.26% | +66.74% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 83.41% | 48.65% | +34.76% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 83.41% | 51.09% | +32.32% |
Dividends
ERAS vs. ASND - Dividend Comparison
Neither ERAS nor ASND has paid dividends to shareholders.
Financials
ERAS vs. ASND - Financials Comparison
This section allows you to compare key financial metrics between Erasca, Inc. and Ascendis Pharma A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ERAS and ASND have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ERAS has higher volatility (20.78%) compared to ASND (13.12%). In terms of maximum drawdown, ERAS dropped -95.65% vs ASND's -61.72%.
ERAS currently has the higher Sharpe Ratio (7.95 vs 0.75), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ERAS and ASND
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer